Short answer
Penumbra Inc (PEN) filed its Q1 2019 10-Q quarterly report on May 7, 2019 for the quarter ended Mar 31, 2019.
Penumbra Inc Q1 2019 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $128.4M, up 25.1% YoY from $102.7M
- Operating margin 8.7% vs 3.9% YoY, gross margin 65.3% vs 64.8%
- Best segment: Vascular revenue $47.0M, up 50.2%; worst: Neuro revenue $81.5M, up 14.1%
- Cash $95.6M vs $67.9M; operating cash flow used $2.1M vs $10.7M provided YoY
- Outlook: continued investment in products, manufacturing, international expansion; competition and foreign exchange headwinds unquantified
Risk Factors
- No risk-factor text provided, so quarter-specific additions or changes cannot be identified
- Regulatory and compliance risk unavailable because the submitted excerpt contains no Item 1A discussion
- Operational and competitive risks unavailable because the submitted excerpt contains no Item 1A discussion
- Financial risk: operating lease liabilities $49,758 thousand recognized after ASC 842 adoption
- Currency risk: foreign currency translation loss $1,098 thousand in Q1 2019
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Penumbra Inc quarterly reports
- Q3 2019 10-QFiled Nov 7, 2019
- Q2 2019 10-QFiled Aug 6, 2019
- Q3 2018 10-QFiled Nov 5, 2018
- Q2 2018 10-QFiled Aug 7, 2018
- Q1 2018 10-QFiled May 8, 2018
- Q3 2017 10-QFiled Nov 7, 2017
- Q2 2017 10-QFiled Aug 8, 2017
- Q1 2017 10-QFiled May 9, 2017
- Q3 2016 10-QFiled Nov 3, 2016
- Q2 2016 10-QFiled Aug 9, 2016
- Q1 2016 10-QFiled May 9, 2016
- Q3 2015 10-QFiled Nov 12, 2015
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.